• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors

    5/16/22 7:30:00 AM ET
    $CRM
    $GILD
    $GOOG
    $HON
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRM alert in real time by email

    Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Robin L. Washington as an independent director effective May 12, 2022. Ms. Washington is among the most experienced business leaders in the biopharmaceutical and technology industries, having served as Chief Financial Officer at Gilead, Inc. from 2008 until 2019, managing global finance, investor relations, facilities and operations, and information technology during a period when corporate revenue grew by more than six-fold.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005352/en/

    Robin L. Washington has been elected to the Eikon Therapeutics Board of Directors. (Photo: Business Wire)

    Robin L. Washington has been elected to the Eikon Therapeutics Board of Directors. (Photo: Business Wire)

    "Robin Washington is an exceptionally skilled independent board member," said Roger M. Perlmutter, CEO and Chairman of Eikon Therapeutics. "There are very few pharmaceutical executives who have been able to manage the sort of extraordinary growth that Robin supervised while at Gilead. Moreover, Robin has had deep operational and boardroom experience at some of the world's most important technology companies. I feel extremely privileged that we will have the benefit of Robin's advice as we chart the course of future expansion at Eikon."

    A Michigan native, and certified public accountant, Robin received a B.A. in Business Administration from the University of Michigan, and an M.B.A. from Pepperdine University. She began her career in finance in 1987 at Tandem Computers, where she also gained experience in managing sales and customer engineering organizations. Beginning in 1999, Robin became vice president and Corporate Treasurer, and later Senior Vice President and Corporate Controller at PeopleSoft, Inc., a financial services, and human resources software development company. Thereafter, from January 2006 until June 2007 she served as Chief Financial Officer at Hyperion Solutions, an enterprise software company. Robin joined Gilead Sciences, Inc. (NASDAQ:GILD) in 2008 as Senior Vice President and Chief Financial Officer, and expanded her role to include operational responsibilities as Executive Vice President from 2014 until her retirement in 2019.

    Beyond these operational roles, Robin has served on the board of Alphabet Inc. (NASDAQ:GOOG, GOOGL))), among the world's most important advanced technology companies, since 2019, and of Honeywell International, Inc. (NASDAQ:HON), a leading multinational conglomerate company with special emphasis on aerospace and building technologies, since 2013. She also serves on the board of Salesforce.com (NYSE:CRM), a global leader in the use of technology for marketing automation and customer relations. Robin is also active in the public sphere: she serves on the President's Council and Ross Business School Advisory Board at the University of Michigan, the Board of Directors of the UCSF Benioff Children's Hospital, Oakland, and the Mastercard Foundation.

    "I am thrilled to have the chance to join the Eikon Therapeutics board, in no small part because it will again give me the opportunity to interact with scientists who are developing the next wave of important new therapies," said Ms. Washington. "My experience at Gilead left me with deep respect for the commitment of discovery researchers, who are inspired by the goal of inventing important new drugs. In my interactions with the Eikon team, I have come away deeply impressed with their technical brilliance, their ambition, and their desire to contribute meaningfully to advances in human health. I am looking forward to helping them in this mission."

    About Eikon Therapeutics

    Eikon Therapeutics is a drug discovery and development company. Our proprietary platform leverages Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing with the goal of bringing important new medicines to patients suffering from grievous illness. Scientists at Eikon measure the real-time movement of individual proteins in living cells to develop differentiated therapeutics. Eikon is based in Hayward, California and can be found online via our website or on Twitter or LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005352/en/

    Get the next $CRM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRM
    $GILD
    $GOOG
    $HON

    CompanyDatePrice TargetRatingAnalyst
    Salesforce Inc.
    $CRM
    9/4/2025$335.00 → $280.00Outperform
    BMO Capital Markets
    Alphabet Inc.
    $GOOG
    9/3/2025$245.00 → $300.00Buy
    Pivotal Research Group
    Salesforce Inc.
    $CRM
    8/26/2025$370.00 → $315.00Outperform
    Oppenheimer
    Gilead Sciences Inc.
    $GILD
    8/19/2025$128.00Neutral → Outperform
    Daiwa Securities
    Salesforce Inc.
    $CRM
    8/15/2025$225.00Underperform → Neutral
    DA Davidson
    Gilead Sciences Inc.
    $GILD
    8/8/2025$127.00Hold → Buy
    Truist
    Gilead Sciences Inc.
    $GILD
    7/25/2025$133.00Hold → Buy
    Needham
    Alphabet Inc.
    $GOOG
    7/24/2025$225.00 → $245.00Buy
    Pivotal Research Group
    More analyst ratings

    $CRM
    $GILD
    $GOOG
    $HON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chair and CEO Benioff Marc exercised 2,250 shares at a strike of $161.50 and sold $543,378 worth of shares (2,250 units at $241.50) (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    9/5/25 4:25:54 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Chair and CEO Benioff Marc exercised 2,250 shares at a strike of $161.50 and sold $572,842 worth of shares (2,250 units at $254.60) (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    9/4/25 4:26:50 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Chair and CEO Benioff Marc exercised 2,250 shares at a strike of $161.50 and sold $566,224 worth of shares (2,250 units at $251.66) (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    9/3/25 5:33:21 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $CRM
    $GILD
    $GOOG
    $HON
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRM
    $GILD
    $GOOG
    $HON
    SEC Filings

    View All

    SEC Form S-8 filed by Salesforce Inc.

    S-8 - Salesforce, Inc. (0001108524) (Filer)

    9/4/25 7:34:08 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-Q filed by Salesforce Inc.

    10-Q - Salesforce, Inc. (0001108524) (Filer)

    9/3/25 9:41:22 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Salesforce Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Salesforce, Inc. (0001108524) (Filer)

    9/3/25 4:03:27 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $CRM
    $GILD
    $GOOG
    $HON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Munoz Oscar bought $998,773 worth of shares (3,882 units at $257.28), increasing direct ownership by 49% to 11,843 units (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    4/4/25 7:36:02 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Director Washington Robin L bought $499,355 worth of shares (1,695 units at $294.61), increasing direct ownership by 4% to 43,445 units (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    3/3/25 5:36:40 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Director Munoz Oscar bought $499,806 worth of shares (2,051 units at $243.69), increasing direct ownership by 41% to 7,026 units (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    6/24/24 6:01:45 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $CRM
    $GILD
    $GOOG
    $HON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets reiterated coverage on Salesforce with a new price target

    BMO Capital Markets reiterated coverage of Salesforce with a rating of Outperform and set a new price target of $280.00 from $335.00 previously

    9/4/25 7:56:17 AM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Pivotal Research Group reiterated coverage on Alphabet with a new price target

    Pivotal Research Group reiterated coverage of Alphabet with a rating of Buy and set a new price target of $300.00 from $245.00 previously

    9/3/25 2:20:08 PM ET
    $GOOG
    Computer Software: Programming Data Processing
    Technology

    Oppenheimer reiterated coverage on Salesforce with a new price target

    Oppenheimer reiterated coverage of Salesforce with a rating of Outperform and set a new price target of $315.00 from $370.00 previously

    8/26/25 8:01:14 AM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $CRM
    $GILD
    $GOOG
    $HON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PubMatic Files Lawsuit Against Google to Restore Fair Competition and Innovation in Digital Advertising

    Seeks Financial Damages and to Hold Google Accountable for its Unlawful Actions that Unfairly Constrained the Open Internet Ecosystem Follows U.S. District Court Ruling that Google Illegally Acted as Monopolist PubMatic, Inc. (NASDAQ:PUBM), an independent technology company delivering digital advertising's supply chain of the future, today filed a lawsuit in the U.S. District Court for the Eastern District of Virginia against Google (NASDAQ:GOOG) to seek financial damages and to restore fair competition, following years-long harm caused by Google's proven and repeated monopolistic and anticompetitive behavior in certain digital advertising markets. The lawsuit follows the ruling from

    9/8/25 9:01:00 AM ET
    $GOOG
    $PUBM
    Computer Software: Programming Data Processing
    Technology

    Salesforce Announces Quarterly Dividend

    Salesforce (NYSE:CRM), the world's #1 AI CRM, today announced that its board of directors declared a quarterly cash dividend of $0.416 per share. The dividend is payable October 9, 2025 to shareholders of record on September 17, 2025. About Salesforce Salesforce helps organizations of any size reimagine their business with AI. Agentforce – the first digital labor solution for enterprises – seamlessly integrates with Customer 360 applications, Data Cloud, and Einstein AI to create a limitless workforce, bringing humans and agents together to deliver customer success on a single, trusted platform. Visit www.salesforce.com for more information. View source version on businesswire.com: htt

    9/4/25 9:10:00 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

    – PEPFAR, Coordinated by the U.S. State Department, will Support Delivery of Lenacapavir for PrEP in High-Incidence, Resource-Limited Countries as Key Part of Strategic Efforts with Global Fund to Accelerate Access – Gilead Sciences, Inc. (NASDAQ:GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead's larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fund, to further advance

    9/4/25 2:15:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRM
    $GILD
    $GOOG
    $HON
    Leadership Updates

    Live Leadership Updates

    View All

    Honeywell Appoints Peter Lau to Lead Industrial Automation

    CHARLOTTE, N.C., Aug. 22, 2025 /PRNewswire/ -- Honeywell (NASDAQ:HON) today announced the appointment of Peter Lau as President and CEO of its Industrial Automation business, effective October 15, 2025.  A former President of Honeywell's Security, Fire and Electrical Products businesses, Lau is returning to succeed Lucian Boldea, who is departing the company at the end of the month to pursue another opportunity. Lau will be based in Charlotte, N.C., and will report to Vimal Kapur, Chairman and CEO of Honeywell. Lau most recently served as President and CEO of FARO Technologies

    8/22/25 8:30:00 AM ET
    $HON
    Aerospace
    Industrials

    Salesforce Appoints Amy Chang and David B. Kirk to its Board of Directors

    New directors deepen the Board's innovation leadership and technical expertise for the agentic AI era Salesforce (NYSE:CRM), the world's #1 AI CRM, today announced the appointments of Amy Chang, accomplished technology executive, AI entrepreneur, and advisor, and David Kirk, pioneering computer scientist and former NVIDIA chief scientist, to the Salesforce Board of Directors, effective immediately. "I'm thrilled to welcome Amy and David to Salesforce's Board. Their exceptional experience driving innovation and deep technical expertise will be invaluable as we unlock the full potential of human-AI collaboration and digital labor for our customers with Agentforce and across our deeply uni

    7/9/25 9:00:00 AM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    HONEYWELL APPOINTS MARC STEINBERG TO BOARD OF DIRECTORS

    CHARLOTTE, N.C., May 28, 2025 /PRNewswire/ -- Honeywell (NASDAQ:HON) announced today that its Board of Directors has elected Marc Steinberg, a Partner at Elliott Investment Management, L.P., to its Board of Directors as an independent Director and Audit Committee member, effective May 31, 2025. As a Partner at Elliott, Steinberg is responsible for public and private equity investments across a range of industries, including the industrials sector. Prior to joining Elliott in 2015, he worked at investment bank Centerview Partners. His extensive financial expertise spans capital

    5/28/25 7:00:00 AM ET
    $HON
    Aerospace
    Industrials

    $CRM
    $GILD
    $GOOG
    $HON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Salesforce Inc.

    SC 13G/A - Salesforce, Inc. (0001108524) (Subject)

    11/14/24 1:22:34 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by Salesforce Inc.

    SC 13G - Salesforce, Inc. (0001108524) (Subject)

    10/16/24 12:53:21 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Salesforce Inc. (Amendment)

    SC 13G/A - Salesforce, Inc. (0001108524) (Subject)

    2/13/24 5:13:53 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $CRM
    $GILD
    $GOOG
    $HON
    Financials

    Live finance-specific insights

    View All

    Salesforce Announces Quarterly Dividend

    Salesforce (NYSE:CRM), the world's #1 AI CRM, today announced that its board of directors declared a quarterly cash dividend of $0.416 per share. The dividend is payable October 9, 2025 to shareholders of record on September 17, 2025. About Salesforce Salesforce helps organizations of any size reimagine their business with AI. Agentforce – the first digital labor solution for enterprises – seamlessly integrates with Customer 360 applications, Data Cloud, and Einstein AI to create a limitless workforce, bringing humans and agents together to deliver customer success on a single, trusted platform. Visit www.salesforce.com for more information. View source version on businesswire.com: htt

    9/4/25 9:10:00 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

    – PEPFAR, Coordinated by the U.S. State Department, will Support Delivery of Lenacapavir for PrEP in High-Incidence, Resource-Limited Countries as Key Part of Strategic Efforts with Global Fund to Accelerate Access – Gilead Sciences, Inc. (NASDAQ:GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead's larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fund, to further advance

    9/4/25 2:15:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Salesforce Reports Record Second Quarter Fiscal 2026 Results

    Exceeds Guidance Across All Metrics; Subscription & Support Revenue up 11% Y/Y, 9% in CC Salesforce (NYSE:CRM), the world's #1 AI CRM, today announced results for its second quarter fiscal 2026 ended July 31, 2025. Results Second quarter revenue of $10.2 billion, up 10% year-over-year ("Y/Y") and 9% in constant currency ("CC") Second quarter subscription & support revenue of $9.7 billion, up 11% Y/Y and 9% in CC Current remaining performance obligation of $29.4 billion, up 11% Y/Y and 10% in CC Second quarter GAAP operating margin of 22.8% and non-GAAP operating margin of 34.3% Returned $2.6 billion to shareholders, including $2.2 billion in share repurchases and $399 mil

    9/3/25 4:01:00 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology